PET Imaging of Hepatocellular Carcinoma

Eric Ehman, Scott M. Thompson, Brian T. Welch, Derek R. Johnson, Hugh C.J. McGregor

Research output: Contribution to journalReview article

Abstract

Purpose of Review: Positron emission tomography has not traditionally played a major role in the evaluation of hepatocellular carcinoma (HCC). Owing to high background liver uptake and molecular mechanisms within HCC lesions, uptake of 18F-fluorodeoxyglucose (FDG) is variable and prior studies have shown only modest overall detection of intrahepatic disease. Recent Findings: Tracers such as 18F- and 11C-choline as well as 11C-acetate have been explored either in isolation or together with 18F-FDG have shown greater promise in detection of intrahepatic lesions, but yet are not in widespread clinical use. 68 Ga-Prostate specific membrane antigen is a tracer developed for use in prostate cancer but a pilot study and several case reports have indicated that there may be the potential for use in the evaluation of HCC. Summary: Increased rates of lesion detection using 18F-FDG may be seen in poorly differentiated tumors and in the setting of metastatic disease or within recurrent tumor following loco-regional therapies and FDG uptake may indicate a greater risk of recurrence following transplantation. Further work will be required to elucidate the precise role of other non FDG tracers in the evaluation of patients at risk for or with HCC.

Original languageEnglish (US)
Article number18
JournalCurrent Radiology Reports
Volume7
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Hepatocellular Carcinoma
Fluorodeoxyglucose F18
Positron-Emission Tomography
Neoplasms
Prostatic Neoplasms
Transplantation
Recurrence
Liver
Therapeutics

Keywords

  • Acetate
  • Choline
  • FDG
  • Hepatocellular carcinoma
  • PET
  • PSMA

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Ehman, E., Thompson, S. M., Welch, B. T., Johnson, D. R., & McGregor, H. C. J. (2019). PET Imaging of Hepatocellular Carcinoma. Current Radiology Reports, 7(6), [18]. https://doi.org/10.1007/s40134-019-0329-5

PET Imaging of Hepatocellular Carcinoma. / Ehman, Eric; Thompson, Scott M.; Welch, Brian T.; Johnson, Derek R.; McGregor, Hugh C.J.

In: Current Radiology Reports, Vol. 7, No. 6, 18, 01.06.2019.

Research output: Contribution to journalReview article

Ehman, E, Thompson, SM, Welch, BT, Johnson, DR & McGregor, HCJ 2019, 'PET Imaging of Hepatocellular Carcinoma', Current Radiology Reports, vol. 7, no. 6, 18. https://doi.org/10.1007/s40134-019-0329-5
Ehman E, Thompson SM, Welch BT, Johnson DR, McGregor HCJ. PET Imaging of Hepatocellular Carcinoma. Current Radiology Reports. 2019 Jun 1;7(6). 18. https://doi.org/10.1007/s40134-019-0329-5
Ehman, Eric ; Thompson, Scott M. ; Welch, Brian T. ; Johnson, Derek R. ; McGregor, Hugh C.J. / PET Imaging of Hepatocellular Carcinoma. In: Current Radiology Reports. 2019 ; Vol. 7, No. 6.
@article{ee7feb0135794439b591972e810b7bec,
title = "PET Imaging of Hepatocellular Carcinoma",
abstract = "Purpose of Review: Positron emission tomography has not traditionally played a major role in the evaluation of hepatocellular carcinoma (HCC). Owing to high background liver uptake and molecular mechanisms within HCC lesions, uptake of 18F-fluorodeoxyglucose (FDG) is variable and prior studies have shown only modest overall detection of intrahepatic disease. Recent Findings: Tracers such as 18F- and 11C-choline as well as 11C-acetate have been explored either in isolation or together with 18F-FDG have shown greater promise in detection of intrahepatic lesions, but yet are not in widespread clinical use. 68 Ga-Prostate specific membrane antigen is a tracer developed for use in prostate cancer but a pilot study and several case reports have indicated that there may be the potential for use in the evaluation of HCC. Summary: Increased rates of lesion detection using 18F-FDG may be seen in poorly differentiated tumors and in the setting of metastatic disease or within recurrent tumor following loco-regional therapies and FDG uptake may indicate a greater risk of recurrence following transplantation. Further work will be required to elucidate the precise role of other non FDG tracers in the evaluation of patients at risk for or with HCC.",
keywords = "Acetate, Choline, FDG, Hepatocellular carcinoma, PET, PSMA",
author = "Eric Ehman and Thompson, {Scott M.} and Welch, {Brian T.} and Johnson, {Derek R.} and McGregor, {Hugh C.J.}",
year = "2019",
month = "6",
day = "1",
doi = "10.1007/s40134-019-0329-5",
language = "English (US)",
volume = "7",
journal = "Current Radiology Reports",
issn = "2167-4825",
publisher = "Springer New York LLC",
number = "6",

}

TY - JOUR

T1 - PET Imaging of Hepatocellular Carcinoma

AU - Ehman, Eric

AU - Thompson, Scott M.

AU - Welch, Brian T.

AU - Johnson, Derek R.

AU - McGregor, Hugh C.J.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Purpose of Review: Positron emission tomography has not traditionally played a major role in the evaluation of hepatocellular carcinoma (HCC). Owing to high background liver uptake and molecular mechanisms within HCC lesions, uptake of 18F-fluorodeoxyglucose (FDG) is variable and prior studies have shown only modest overall detection of intrahepatic disease. Recent Findings: Tracers such as 18F- and 11C-choline as well as 11C-acetate have been explored either in isolation or together with 18F-FDG have shown greater promise in detection of intrahepatic lesions, but yet are not in widespread clinical use. 68 Ga-Prostate specific membrane antigen is a tracer developed for use in prostate cancer but a pilot study and several case reports have indicated that there may be the potential for use in the evaluation of HCC. Summary: Increased rates of lesion detection using 18F-FDG may be seen in poorly differentiated tumors and in the setting of metastatic disease or within recurrent tumor following loco-regional therapies and FDG uptake may indicate a greater risk of recurrence following transplantation. Further work will be required to elucidate the precise role of other non FDG tracers in the evaluation of patients at risk for or with HCC.

AB - Purpose of Review: Positron emission tomography has not traditionally played a major role in the evaluation of hepatocellular carcinoma (HCC). Owing to high background liver uptake and molecular mechanisms within HCC lesions, uptake of 18F-fluorodeoxyglucose (FDG) is variable and prior studies have shown only modest overall detection of intrahepatic disease. Recent Findings: Tracers such as 18F- and 11C-choline as well as 11C-acetate have been explored either in isolation or together with 18F-FDG have shown greater promise in detection of intrahepatic lesions, but yet are not in widespread clinical use. 68 Ga-Prostate specific membrane antigen is a tracer developed for use in prostate cancer but a pilot study and several case reports have indicated that there may be the potential for use in the evaluation of HCC. Summary: Increased rates of lesion detection using 18F-FDG may be seen in poorly differentiated tumors and in the setting of metastatic disease or within recurrent tumor following loco-regional therapies and FDG uptake may indicate a greater risk of recurrence following transplantation. Further work will be required to elucidate the precise role of other non FDG tracers in the evaluation of patients at risk for or with HCC.

KW - Acetate

KW - Choline

KW - FDG

KW - Hepatocellular carcinoma

KW - PET

KW - PSMA

UR - http://www.scopus.com/inward/record.url?scp=85064488131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064488131&partnerID=8YFLogxK

U2 - 10.1007/s40134-019-0329-5

DO - 10.1007/s40134-019-0329-5

M3 - Review article

AN - SCOPUS:85064488131

VL - 7

JO - Current Radiology Reports

JF - Current Radiology Reports

SN - 2167-4825

IS - 6

M1 - 18

ER -